Latest Period
Q1 2026
Security Snapshot
Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) Institutional Ownership
CUSIP: 22053A107
13F Institutional Holders and Ownership History from Q2 2019 to Q1 2026
Institutions Reporting
38
Shares (Excl. Options)
14,164,823
Price
$0.10
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- QNCX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 14,164,823
- Total 13F value
- $1,434,880
- Portfolio coverage rank
- 0%
- Share change
- -4,607,782
- Value change
- -$39,161,496
- Number of holders
- 38
- Shares outstanding
- 60,216,782
- SEC-reported price per share
- $0.14
- Insider filing price
- $0.14
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- QNCX - Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 22053A107.
- 38 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 67 to 38 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $67,479,982 to $1,434,880.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 38 institutions filings for Q1 2026.
Security key
22053A107
Latest holder period
Q1 2026
13F holders
38
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
QNCX full holder history
Quince Therapeutics, Inc. SEC filings
Quince Therapeutics, Inc. company facts
Quince Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 22053A107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
QNCX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GROUP ONE TRADING LLC | 11% | $3,625,173 | 5,942,906 | GROUP ONE TRADING LLC | 28 Feb 2026 | |||
| Nantahala Capital Management, LLC | 7.5% | -25% | $633,962 | -$152,897 | 4,528,302 | -19% | Nantahala Capital Management, LLC | 31 Mar 2026 |
| Sofinnova Partners SAS | 2.7% | -54% | $1,185,734 | -$1,188,000 | 1,197,711 | -50% | Sofinnova Capital VIII | 31 Mar 2025 |
As of 31 Mar 2026, 38 institutional investors reported holding 14,164,823 shares of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX). This represents 24% of the company’s total 60,216,782 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
23%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Woodline Partners LP | 8.6% | 5,200,000 | +168% | 0% | $527,280 |
| MILLENNIUM MANAGEMENT LLC | 4.2% | 2,503,717 | +110% | 0% | $253,877 |
| Shay Capital LLC | 2.9% | 1,772,909 | 0.03% | $179,773 | |
| ACADIAN ASSET MANAGEMENT LLC | 2.9% | 1,750,862 | +10014% | 0% | $176,000 |
| IEQ CAPITAL, LLC | 1% | 600,105 | -39% | 0% | $60,851 |
| BlackRock, Inc. | 0.79% | 473,259 | +0.27% | 0% | $47,989 |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.77% | 461,477 | 0% | 0% | $46,609 |
| STATE STREET CORP | 0.41% | 248,011 | +7.5% | 0% | $25,148 |
| VANGUARD FIDUCIARY TRUST CO | 0.39% | 232,326 | 0% | 0% | $23,465 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.29% | 172,640 | -50% | 0% | $17,506 |
| SIMPLEX TRADING, LLC | 0.26% | 154,093 | -7.8% | 0% | $15,563 |
| Vanguard Personalized Indexing Management, LLC | 0.22% | 132,661 | 0% | $13,452 | |
| TWO SIGMA INVESTMENTS, LP | 0.12% | 71,223 | -61% | 0% | $7,222 |
| NORTHERN TRUST CORP | 0.11% | 65,930 | -38% | 0% | $6,685 |
| Intellectus Partners, LLC | 0.09% | 53,312 | 0% | 0% | $5,406 |
| ADAR1 Capital Management, LLC | 0.08% | 50,100 | +17% | 0% | $5,080 |
| XTX Topco Ltd | 0.08% | 48,812 | +291% | 0% | $4,950 |
| Nordwand Advisors, LLC | 0.03% | 20,000 | 0% | $2,028 | |
| Vanguard Global Advisers, LLC | 0.03% | 19,514 | 0% | 0% | $1,971 |
| Scharf Investments, LLC | 0.03% | 19,461 | -79% | 0% | $1,973 |
| GOLDMAN SACHS GROUP INC | 0.03% | 16,064 | -93% | 0% | $1,629 |
| Cambridge Investment Research Advisors, Inc. | 0.03% | 15,200 | 0% | 0% | $2,000 |
| Belvedere Trading LLC | 0.02% | 13,080 | 0% | $1,321 | |
| Alpha Zero LLC | 0.02% | 13,000 | 0% | $1,318 | |
| Mariner, LLC | 0.02% | 12,673 | 0% | $1,285 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
28
Latest
Q1 2026
Rows shown
1-25 of 28
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 14,164,823 | $1,434,880 | -$39,161,496 | $0.10 | 38 |
| 2025 Q4 | 20,143,303 | $67,479,982 | +$28,429,772 | $3.35 | 67 |
| 2025 Q3 | 11,792,663 | $19,221,893 | +$6,863,019 | $1.63 | 45 |
| 2025 Q2 | 7,578,787 | $12,505,248 | +$3,952,656 | $1.65 | 40 |
| 2025 Q1 | 5,230,260 | $6,956,589 | +$1,241,119 | $1.33 | 35 |
| 2024 Q4 | 5,108,991 | $9,553,550 | +$495,078 | $1.87 | 34 |
| 2024 Q3 | 5,193,769 | $4,039,786 | -$775,970 | $0.78 | 32 |
| 2024 Q2 | 6,247,425 | $4,679,876 | -$811,761 | $0.75 | 41 |
| 2024 Q1 | 7,272,011 | $7,707,118 | -$189,424 | $1.06 | 44 |
| 2023 Q4 | 7,451,323 | $7,825,763 | -$54,129 | $1.05 | 41 |
| 2023 Q3 | 7,501,451 | $8,401,710 | -$2,281,471 | $1.12 | 40 |
| 2023 Q2 | 8,974,632 | $13,507,225 | +$1,945,492 | $1.50 | 38 |
| 2023 Q1 | 7,677,996 | $11,976,762 | +$3,808,602 | $1.56 | 41 |
| 2022 Q4 | 5,400,142 | $3,438,849 | -$3,310,463 | $0.64 | 46 |
| 2022 Q3 | 9,314,202 | $12,384,077 | -$3,927,969 | $1.33 | 51 |
| 2022 Q2 | 11,700,511 | $25,971,549 | -$20,267,021 | $2.22 | 60 |
| 2022 Q1 | 14,236,792 | $88,111,251 | -$45,899,789 | $6.19 | 83 |
| 2021 Q4 | 19,237,596 | $242,781,654 | -$219,571,461 | $12.62 | 95 |
| 2021 Q3 | 19,191,414 | $1,759,087,977 | +$80,924,604 | $91.66 | 130 |
| 2021 Q2 | 18,545,330 | $982,908,976 | -$6,104,699 | $53.00 | 104 |
| 2021 Q1 | 18,693,040 | $673,491,454 | +$37,011,077 | $36.03 | 90 |
| 2020 Q4 | 17,656,872 | $490,520,403 | +$26,833,435 | $27.78 | 84 |
| 2020 Q3 | 16,543,535 | $826,995,550 | +$55,308,755 | $50.00 | 85 |
| 2020 Q2 | 15,442,796 | $714,739,484 | +$184,954,170 | $46.30 | 82 |
| 2020 Q1 | 11,450,501 | $522,757,976 | +$39,593,805 | $45.61 | 65 |